Biochemical alterations |
Presence of anti-Aspergillus antibodies forming immune complexes |
Bilirubin ≥20 mg/L |
Triglycerides ≥200 mg/dL |
Hemoglobin ≥500 mg/dL |
Use of cytotoxic chemotherapeutic agents (promoting damage to the intestinal mucosa) |
Storage of samples at room temperature for a prolonged period before processing |
Graft versus host disease and autoreactive antibodies |
High serum albumin levels |
Bacteremia by Pseudomonas spp. or Escherichia coli
|
Presence of galactomannan-degrading enzymes in biological material |
Use of β-lactams such as piperacillin-tazobactam, amoxicillin/clavulanic acid |
Prior use of antifungal agents |
IFIs by other fungi: |
Chronic granulomatous disease and Job's syndrome (hyperimmunoglobulin E) |
Fusarium |
Cryptococcus |
Histoplasma |
Penicilium |
Alternaria |
Paecilomyces |
Geotricum |
Yarrowia lipolytica |
Alterations of intestinal mucosa (intake of cereal and cow milk) |
Lack of neutropenia |
Neonates colonized by Bifidobacterium spp. |
|
Gluconate-containing Plasma-Lyte |
|
Other intravenous fluids containing gluconate |
|
Possibly cardboard or soybean protein |
|